B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors

  • Tomonori Kaifu
  • Bertrand Escalière
  • Louis N. Gastinel
  • Eric Vivier
  • Myriam BaratinEmail author
Multi-author review


Natural killer (NK) cells are lymphocytes of the innate immune system that sense target cells through a panel of activating and inhibitory receptors. Together with NKG2D, the natural cytotoxicity receptors (NCRs) are major activating receptors involved in tumor cell detection. Although numerous NKG2D ligands have been identified, characterization of the molecules interacting with the NCRs is still incomplete. The identification of B7-H6 as a counter structure of the NCR NKp30 shed light on the molecular basis of NK cell immunosurveillance. We review here the current knowledge on NKp30 and B7-H6, and we discuss their potential role in anti-tumor immunity.


NK cell Activating receptor NKp30 B7-H6 Tumor immunosurveillance 


  1. 1.
    Herberman RB, Nunn ME, Lavrin DH (1975) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. distribution of reactivity and specificity. Int J Cancer 16:216–229PubMedCrossRefGoogle Scholar
  2. 2.
    Kiessling R, Klein E, Wigzell H (1975) “Natural” killer cells in the mouse. I. cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5:112–117PubMedCrossRefGoogle Scholar
  3. 3.
    Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510PubMedCrossRefGoogle Scholar
  4. 4.
    Vivier E, Nunes JA, Vely F (2004) Natural killer cell signaling pathways. Science 306:1517–1519PubMedCrossRefGoogle Scholar
  5. 5.
    Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675–678PubMedCrossRefGoogle Scholar
  6. 6.
    Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225–274PubMedCrossRefGoogle Scholar
  7. 7.
    Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235:267–285PubMedGoogle Scholar
  8. 8.
    Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C (2007) Expression analysis of the ligands for the natural killer cell receptors NKp30 and NKp44. PLoS One 2:e1339PubMedCrossRefGoogle Scholar
  9. 9.
    Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, Negri F, Conte R, Corrias MV, Moretta L, Moretta A, Bottino C (2004) Identification of 4Ig-B7–H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 101:12640–12645PubMedCrossRefGoogle Scholar
  10. 10.
    Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190:1505–1516PubMedCrossRefGoogle Scholar
  11. 11.
    Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178–6186PubMedGoogle Scholar
  12. 12.
    Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409:1055–1060PubMedCrossRefGoogle Scholar
  13. 13.
    Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31:2680–2689PubMedCrossRefGoogle Scholar
  14. 14.
    Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E, Porgador A, Honigman A, Plachter B, Mevorach D, Wolf DG, Mandelboim O (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6:515–523PubMedCrossRefGoogle Scholar
  15. 15.
    Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Boll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A (2007) Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27:965–974PubMedCrossRefGoogle Scholar
  16. 16.
    Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 206:1495–1503PubMedCrossRefGoogle Scholar
  17. 17.
    Ponnampalam AP, Gargett CE, Rogers PA (2008) Identification and hormonal regulation of a novel form of NKp30 in human endometrial epithelium. Eur J Immunol 38:216–226PubMedCrossRefGoogle Scholar
  18. 18.
    Tang Q, Grzywacz B, Wang H, Kataria N, Cao Q, Wagner JE, Blazar BR, Miller JS, Verneris MR (2008) Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol 181:4507–4515PubMedGoogle Scholar
  19. 19.
    Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, Fibbe WE, Cornelissen JJ, Spits H (2009) Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 10:66–74PubMedCrossRefGoogle Scholar
  20. 20.
    Vivier E, Spits H, Cupedo T (2009) Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol 9:229–234PubMedCrossRefGoogle Scholar
  21. 21.
    Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195:343–351PubMedCrossRefGoogle Scholar
  22. 22.
    Vitale M, Della Chiesa M, Carlomagno S, Pende D, Arico M, Moretta L, Moretta A (2005) NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 106:566–571PubMedCrossRefGoogle Scholar
  23. 23.
    Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, Moretta L, Moretta A, Vitale M (2006) The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108:4118–4125PubMedCrossRefGoogle Scholar
  24. 24.
    Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100:4120–4125PubMedCrossRefGoogle Scholar
  25. 25.
    Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109:323–330PubMedCrossRefGoogle Scholar
  26. 26.
    Walzer T, Jaeger S, Chaix J, Vivier E (2007) Natural killer cells: from CD3(−) NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol 19:365–372PubMedCrossRefGoogle Scholar
  27. 27.
    Hollyoake M, Campbell RD, Aguado B (2005) NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli. Mol Biol Evol 22:1661–1672PubMedCrossRefGoogle Scholar
  28. 28.
    Rutjens E, Mazza S, Biassoni R, Koopman G, Radic L, Fogli M, Costa P, Mingari MC, Moretta L, Heeney J, De Maria A (2007) Differential NKp30 inducibility in chimpanzee NK cells and conserved NK cell phenotype and function in long-term HIV-1-infected animals. J Immunol 178:1702–1712PubMedGoogle Scholar
  29. 29.
    Krieger E, Joo K, Lee J, Raman S, Thompson J, Tyka M, Baker D, Karplus K (2009) Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: four approaches that performed well in CASP8. Proteins 77(Suppl 9):114–122PubMedCrossRefGoogle Scholar
  30. 30.
    Neville MJ, Campbell RD (1999) A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC. J Immunol 162:4745–4754PubMedGoogle Scholar
  31. 31.
    Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Celis Gutierrez J, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L (2011) Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 17:700–707Google Scholar
  32. 32.
    Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D (2003) Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 197:1427–1439PubMedCrossRefGoogle Scholar
  33. 33.
    Zhi L, Mans J, Paskow MJ, Brown PH, Schuck P, Jonjic S, Natarajan K, Margulies DH (2010) Direct interaction of the mouse cytomegalovirus m152/gp40 immunoevasin with RAE-1 isoforms. Biochemistry 49:2443–2453PubMedCrossRefGoogle Scholar
  34. 34.
    Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, Hanna J, Qimron U, Landau G, Greenbaum E, Zakay-Rones Z, Porgador A, Mandelboim O (2006) Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 7:517–523PubMedCrossRefGoogle Scholar
  35. 35.
    Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E (2008) Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One 3:e3377PubMedCrossRefGoogle Scholar
  36. 36.
    Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548PubMedCrossRefGoogle Scholar
  37. 37.
    Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8:467–477PubMedCrossRefGoogle Scholar
  38. 38.
    Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198:557–567PubMedCrossRefGoogle Scholar
  39. 39.
    Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:1186–1190PubMedCrossRefGoogle Scholar
  40. 40.
    Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR (2008) Interaction of monocytes with NK cells upon toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol 181:6711–6719PubMedGoogle Scholar
  41. 41.
    Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vely F, Pende D, Trowsdale J, Vivier E, Gordon S, Davis DM (2007) Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 109:3776–3785PubMedCrossRefGoogle Scholar
  42. 42.
    Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD (2006) IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 176:905–913PubMedGoogle Scholar
  43. 43.
    Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, Miyagi T, Suzuki T, Sasaki Y, Hayashi N (2003) Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 170:1249–1256PubMedGoogle Scholar
  44. 44.
    Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M, Mandelboim O (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9:1065–1073PubMedCrossRefGoogle Scholar
  45. 45.
    Gong AY, Zhou R, Hu G, Li X, Splinter PL, O’Hara SP, LaRusso NF, Soukup GA, Dong H, Chen XM (2009) MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol 182:1325–1333PubMedCrossRefGoogle Scholar
  46. 46.
    Xu H, Cheung IY, Guo HF, Cheung NK (2009) MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69:6275–6281PubMedCrossRefGoogle Scholar
  47. 47.
    Nice TJ, Coscoy L, Raulet DH (2009) Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress. J Exp Med 206:287–298PubMedCrossRefGoogle Scholar
  48. 48.
    Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR (2008) Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 14:3520–3528PubMedCrossRefGoogle Scholar
  49. 49.
    Vales-Gomez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT (2008) Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res 68:1546–1554PubMedCrossRefGoogle Scholar
  50. 50.
    Salih HR, Rammensee HG, Steinle A (2002) Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169:4098–4102PubMedGoogle Scholar
  51. 51.
    Cao W, Xi X, Hao Z, Li W, Kong Y, Cui L, Ma C, Ba D, He W (2007) RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J Biol Chem 282:18922–18928PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2011

Authors and Affiliations

  • Tomonori Kaifu
    • 1
  • Bertrand Escalière
    • 2
    • 3
    • 4
  • Louis N. Gastinel
    • 5
  • Eric Vivier
    • 2
    • 3
    • 4
    • 6
  • Myriam Baratin
    • 2
    • 3
    • 4
    Email author
  1. 1.Center for Experimental Medicine and Systems Biology, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  2. 2.Centre d’Immunologie de Marseille-LuminyUniversité de la MéditerranéeMarseilleFrance
  3. 3.INSERM U631MarseilleFrance
  4. 4.Centre National de la Recherche ScientifiqueUMR6102MarseilleFrance
  5. 5.INSERM UMR-S850, Laboratoire de Pharmacologie des Immunosuppresseurs en Transplantation, Faculté de Médecine et de PharmacieUniversité de LimogesLimogesFrance
  6. 6.Hôpital de la ConceptionAssistance Publique-Hôpitaux de MarseilleMarseilleFrance

Personalised recommendations